Modified Immune Cell Therapy Induces Kidney-Donor-Specific Immunosuppression


Patients treated with the highest dose of MIC-Lx had lymphocyte reactivity against third-party cells but not stimulatory donor blood cells.

MIC-Lx cell therapy (TolerogenixX) induced long-term donor-specific immunosuppression and yielded a significant increase in regulatory B lymphocytes in kidney transplant recipients, according to 3-year follow-up data from a phase 1 study (NCT02560220).1

Patients treated with the modified immune cell (MIC) therapy had no donor-specific human leukocyte antigen (HLA) antibodies or acute rejections. The 4 patients who received the highest dose of MIC-LX (1.5 × 108) 7 days before surgery were on reduced immunosuppressive therapy and did not have in vitro lymphocyte reactivity against stimulatory donor blood cells while reactivity against third-party cells was preserved. These patients also had 75-fold and 7-fold higher numbers of transitional B lymphocytes than in 12 long-term survivors on minimal immunosuppression and 4 operationally tolerant patients, respectively (P <.001).

"MIC treatment is leading to an operationally tolerant phenotype of patients with profound suppression of anti-donor T cell responses," first author Prof. Dr. Christian Morath, chief scientific officer, TolerogenixX, said in a statement.2 "The 1-year follow-up data published in 2020 already showed excellent safety and tolerability of our treatment, and we are very happy that these favorable results hold up in the three-year follow-up."

The study treated 10 patients with 1.5 × 106 MIC per kg body weight on day -2 (n = 3, group A) or 1.5 × 108 MIC per kg body weight on day -2 (n = 3, group B) or day -7 (n = 4, group C) prior to living donor kidney transplantation, in addition to post-transplant immunosuppression with CyA, EC-MPS, and methylprednisolone.

WATCH NOW: Tackling Deceased Kidney Transplant and Severe Scleroderma With Cell Therapy

Over 3 years of follow up, there were no cases of de novo donor-specific antibodies or acute rejection episodes. Investigators found that kidney graft function was stable with a median serum creatinine of 1.40 mg/dL (range, 1.04-2.10), a median estimated glomerular filtration rate (according to the Chronic Kidney Disease Epidemiology Collaboration score) of 61 mL/min/1.73 m2 (range 41–93), and a median urinary protein excretion of 14 g/moL creatinine (range 5–90).

There were no cases of opportunistic infections and no cytomegalovirus or BKV replications during posttransplant screening. Six patients had 12 non-opportunistic infections, 2 of which occurred during the second and third years of follow-up. There were no cases of malignancy or posttransplant lymphoproliferative disorders.

"The results once again demonstrate that we generate an immunoregulatory cell population which carries the promise of exerting a beneficial effect on kidney transplants," author Prof. Dr. Matthias Schaier, chief executive officer, TolerogenixX, added to the statement.2

Investigators found that percentage of regulatory B lymphocytes increased from a median of 6% (range, 0-11) of the total lymphocyte pool to 20% (range, 5-40) on day 180 before dropping to a median of 8% (range, 5-13) by day 720 and remaining stable until day 1080. These levels were not only higher than baseline but also levels in literature for stable immunosuppressed (range, 0-5%) and operationally tolerant patients (range, 3-8%).

Gene expression analysis revealedthat 3 of 4 patients in Group C had the COMBINED-g7 consensus gene-expression signature of operational tolerance.They also determined that interleukin-10-producing transitional B lymphocytes were functionally relevant for donor-specific unresponsiveness.

"These new results show that the effect is long-lasting and associated with a striking increase in regulatory B lymphocytes. They underline the importance of MIC-Lx in paving the way for a novel cell therapy in organ transplantation,” PD Dr. Anita Schmitt, chief technical officer, TolerogenixX, added to the statement.2

Investigators are now conducting a phase 2 study (NCT05365672) to expand the findings seen in the 4 patients in Group C, compared to patients treated with standard of care. Patients in the phase 2 study will hopefully develop an operationally tolerant-like phenotype.

1. Morath C, Schaier M, Ibrahim E, et al. Induction of long-lasting regulatory B lymphocytes by modified immune cells in kidney transplant recipients. J. Am. Soc. Nephrol. Published online September 22, 2022. doi: 10.1681/ASN.2022020210
2. TolerogenixX publishes three-year follow-up data from phase i trial of immune tolerance-inducing MIC-Lx cell therapy. News release. TolerogenixX. September 26, 2022.
Related Videos
Julie Kanter, MD
Mark Walters, MD
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Farah Sheikh, PhD, on Continuing Gene Therapy Research Into Arrhythmias, Cardiac Dysfunction
Binod Dhakal, MD, on Benefit of Cilta-Cel in Earlier Lines of Multiple Myeloma Treatment
Thomas Povsic, MD, PhD, on EXACT Clinical Trial: Investigating Gene Therapy for Refractory Angina
Joseph Fraietta, PhD, on Achieving a Deeper Understanding of CAR T-Cell Therapy
© 2023 MJH Life Sciences

All rights reserved.